Review on Cost Effectiveness of Shingles Vaccine

Mr Christopher de Souza asked the Minister for Health (a) whether the review of the cost effectiveness of shingles vaccine has been completed; and (b) if so, whether the Ministry will add it to the National Adult Immunisation Schedule such that it will be eligible for subsidies, especially for vulnerable seniors.

Mr Ong Ye Kung: The review of the cost effectiveness of the shingles vaccine, Shingrix, has been completed. At the price proposed by the manufacturer, the vaccine is not considered cost-effective for the prevention of shingles at the population level. We will continue to discuss with the manufacturer and monitor their pricing.